




RealRate

PHARMACEUTICAL 2019

Corbus Pharmaceuticals Holdings Inc. Rank 271 of 363





RealRate

PHARMACEUTICAL 2019

Corbus Pharmaceuticals Holdings Inc. Rank 271 of 363



The relative strengths and weaknesses of Corbus Pharmaceuticals Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Corbus Pharmaceuticals Holdings Inc. compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 20% points. The greatest weakness of Corbus Pharmaceuticals Holdings Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 93% points.

The company's Economic Capital Ratio, given in the ranking table, is -25%, being 62% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	44,240
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,089
Liabilities, Non-Current	0
Other Assets	44
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	1,376
Other Net Income	1,076
Other Revenues	4,822
Property and Equipment	2,705
Research and Development	48,614
Selling, General and Administrative Expense	12,956

Output Variable	Value in 1000 USD
Assets	46,989
Liabilities	19,465
Expenses	61,570
Revenues	4,822
Stockholders Equity	27,524
Net Income	-55,672
Comprehensive Net Income	-55,672
Economic Capital Ratio	-25%